Binding kinetics provide the full picture in biologics development
Sybody™ candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD
With no-clog microfluidics and superior sensitivity to conventional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, here we show how the WAVEsystem is driving biologics development by providing insights into binding affinities and selectivity of Sybody™ candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein
Shedding light on Sybody™ candidates binding onto SARS-CoV-2 Spike RBD
In this TechNote we show how the WAVEsystem can be used to understand the binding dynamics of Sybody™ candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich.
With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.
The experiments behind TechNote 14
Listen to Markus Seeger and Rony Nehmé discuss their collaboration in detail, including why ELISA signals alone cannot predict potency, Markus choice for the WAVEsystem and why it is important to choose the right candidates at the very early stages of research.
In this TechNote we show how the WAVEsystem can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich.
J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”
Thorough testing in our laboratory has convinced us that Creoptix’ WAVE technology aids us best in discovering better drug molecules